A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

NCT05176873 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: DZD8586
DRUG: Placebo

Sponsor

Dizal (Jiangsu) Pharmaceutical Co., Ltd.